Wall Street analyst estimates for Becton, Dickinson and Company (BDX): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products.
Consensus price target
$188.33 (-5 % vs price $198.60)
between $165.00 and $210.00 · 5 targets published in the last quarter
Closing price, Nov 2
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $19.3B | $19.1B – $20.0B | $12.67 | 8 |
| 2027E | $19.7B | $19.4B – $20.4B | $13.25 | 9 |
Fiscal year ending in September · figures in USD · consensus as of November 2, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 16 |
| Hold | 17 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 34 |
| Avg rating (−2 sell to +2 buy) | 0.44 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $4.07 | ||
| 2026-08-06 | $3.23 | $3.14 | +2.9% |
| 2026-05-07 | $2.90 | $2.78 | +4.3% |
| 2026-02-09 | $2.91 | $2.21 | +31.7% |
| 2025-11-06 | $3.96 | $3.92 | +1.0% |
| 2025-08-07 | $3.68 | $3.40 | +8.2% |
| 2025-05-01 | $3.35 | $3.28 | +2.1% |
| 2025-02-05 | $3.43 | $3.00 | +14.3% |
Valuation Ratios
| P/E Ratio | 59.82 |
| Price / Book | 2.24 |
| Dividend Yield | 2.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.48B | $12.09B | $15.98B | $17.29B | $16.07B | $19.13B | $18.87B | $19.37B | $20.18B | $21.84B |
| Cost of Revenue | $6.49B | $6.13B | $8.71B | $9.00B | $9.28B | $10.50B | $10.39B | $11.20B | $11.05B | $11.91B |
| Gross Profit | $5.99B | $5.96B | $7.27B | $8.29B | $6.80B | $8.63B | $8.48B | $8.17B | $9.12B | $9.92B |
| Research & Development | $828.0M | $770.0M | $1.00B | $1.06B | $1.04B | $1.28B | $1.26B | $1.24B | $1.19B | $1.26B |
| Selling, General & Admin | $3.00B | $2.91B | $4.02B | $4.33B | $4.18B | $4.72B | $4.71B | $4.72B | $4.86B | $5.28B |
| Operating Expenses | $4.56B | $4.44B | $5.76B | $6.53B | $5.89B | $6.38B | $6.20B | $6.06B | $6.73B | $7.35B |
| Operating Income | $1.43B | $1.52B | $1.51B | $1.76B | $912.0M | $2.25B | $2.28B | $2.11B | $2.40B | $2.58B |
| EBITDA | $2.58B | $2.58B | $3.86B | $4.07B | $3.06B | $4.39B | $4.41B | $4.40B | $4.82B | $4.96B |
| Interest Expense | $388.0M | $521.0M | $706.0M | $639.0M | $528.0M | $469.0M | $398.0M | $452.0M | $528.0M | $613.0M |
| Pre-tax Income | $1.07B | $976.0M | $1.17B | $1.18B | $414.0M | $1.69B | $1.78B | $1.66B | $2.00B | $1.88B |
| Income Tax | $98.0M | -$124.0M | $862.0M | -$57.0M | $62.0M | $88.0M | $148.0M | $132.0M | $300.0M | $204.0M |
| Net Income | $976.0M | $1.10B | $311.0M | $1.23B | $874.0M | $2.09B | $1.78B | $1.48B | $1.71B | $1.68B |
| EPS | $4.59 | $4.70 | $0.62 | $3.96 | $2.75 | $6.92 | $5.93 | $4.97 | $5.88 | $5.84 |
| EPS (Diluted) | $4.49 | $4.60 | $0.60 | $3.89 | $2.71 | $6.85 | $5.88 | $4.94 | $5.86 | $5.83 |
| Shares Outstanding (Diluted) | 217.5 M | 223.6 M | 264.6 M | 274.8 M | 282.4 M | 292.1 M | 287.4 M | 288.4 M | 291.0 M | 287.1 M |
Price
| Price | $198.60 (closing price, November 2, 2026) |
| Market Cap | $54.1B |
| Exchange | NYSE |
| Country | US |
Related companies: MMSI · ICUI · ABT · MDT · WST · SOLV · BAX · TFX
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of BDX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks